Suppliers and packagers for avgemsi

avgemsi

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920	NDA	Avyxa Pharma, LLC	83831-123-01	1 VIAL, MULTI-DOSE in 1 CARTON (83831-123-01) / 26.3 mL in 1 VIAL, MULTI-DOSE	2025-08-03
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920	NDA	Avyxa Pharma, LLC	83831-124-01	1 VIAL, MULTI-DOSE in 1 CARTON (83831-124-01) / 52.6 mL in 1 VIAL, MULTI-DOSE	2025-08-03

AVGEMSI (Mirvetuximab Soravtansine) Supply Chain Analysis

Last updated: February 19, 2026

Who are the Key Suppliers for AVGEMSI?

The supply chain for AVGEMSI (mirvetuximab soravtansine), an antibody-drug conjugate (ADC) developed by ImmunoGen, Inc. (now part of AbbVie), involves specialized manufacturers for its active pharmaceutical ingredient (API) and finished drug product. ImmunoGen, and subsequently AbbVie, manage these complex manufacturing processes through contracted third-party manufacturers.

Key Suppliers Identified:

• API Manufacturing: The synthesis of mirvetuximab soravtansine is a multi-step process requiring expertise in antibody production and small molecule conjugation.
  • Antibody (Mirvetuximab) Production: Large-scale mammalian cell culture for the antibody component is typically outsourced to Contract Development and Manufacturing Organizations (CDMOs) with significant biomanufacturing capacity and regulatory compliance.
  • Linker-Payload (DM4) Synthesis: The cytotoxic payload (derivative of maytansine, known as DM4) and the linker chemistry are specialized processes. These are often handled by CDMOs with expertise in highly potent APIs (HPAPIs) and complex organic synthesis.
  • Conjugation: The process of chemically linking the antibody to the linker-payload requires specialized facilities and stringent containment due to the high potency of the payload. This is a critical step performed by CDMOs with ADC conjugation capabilities.
• Drug Product Manufacturing: This involves formulating the conjugated ADC into its final sterile dosage form, filling vials, and packaging.
  • Fill-Finish Operations: These services are provided by CDMOs specializing in aseptic processing of biologics and ADCs.

Specific Supplier Identification:

Due to the proprietary nature of pharmaceutical supply chains and the confidential agreements between drug developers and their contract manufacturers, specific supplier names for the API synthesis and drug product manufacturing of AVGEMSI are not publicly disclosed in comprehensive detail. However, industry reports and regulatory filings often point to the types of CDMOs involved.

ImmunoGen, prior to its acquisition by AbbVie, had established manufacturing relationships with specialized CDMOs. AbbVie, as the current owner, continues to manage and potentially optimize these relationships. Companies known for their ADC manufacturing capabilities and often cited in the industry as potential partners include:

• Lonza: A global CDMO with extensive experience in antibody manufacturing, small molecule synthesis, and ADC conjugation services.
• Catalent: Offers integrated services for biologics and ADCs, including cell line development, biomanufacturing, and conjugation.
• AGC Biologics: Provides a broad range of biopharmaceutical manufacturing services, including those relevant to ADC production.
• Bayer Pharmaceuticals (through its life sciences division): Has also been involved in ADC manufacturing collaborations.

It is important to note that the exact suppliers for AVGEMSI can change based on capacity, cost, regulatory approvals, and strategic decisions by AbbVie. The complexity of ADC manufacturing necessitates highly specialized partners.

What are the Manufacturing Challenges for AVGEMSI?

The manufacturing of antibody-drug conjugates (ADCs) like AVGEMSI presents unique and significant challenges, stemming from the inherent complexity of combining a highly potent small molecule toxin with a large therapeutic antibody. These challenges span multiple stages of production and require specialized expertise, infrastructure, and stringent quality control.

Key Manufacturing Challenges:

• Complex Multi-Step Synthesis:
  • Antibody Production: Producing the antibody component (mirvetuximab) requires large-scale mammalian cell culture, demanding precise control over cell growth, protein expression, and purification. Variability in cell culture can impact antibody quality and yield.
  • Payload Synthesis: The cytotoxic payload (DM4 derivative) is a complex small molecule. Its synthesis involves multiple organic chemistry steps, often requiring specialized reagents and conditions, and careful control of impurities.
  • Linker Synthesis: The linker molecule that connects the antibody and the payload also requires specialized chemical synthesis, ensuring its stability and appropriate cleavage properties.
• Potent Payload Handling:
  • Containment: The cytotoxic payload is highly potent and hazardous. Manufacturing facilities must have robust containment systems (e.g., isolators, specialized ventilation) to protect personnel and prevent cross-contamination. This significantly increases facility costs and operational complexity.
  • Operator Safety: Strict protocols and personal protective equipment (PPE) are essential to ensure the safety of personnel working with these potent compounds.
• Conjugation Process:
  • Controlled Drug-to-Antibody Ratio (DAR): Achieving a consistent and precise DAR is critical for efficacy and safety. Inconsistent conjugation can lead to suboptimal drug activity or increased toxicity. This requires precise control over reaction conditions, reagent stoichiometry, and reaction time.
  • Reaction Specificity: Ensuring that the payload is conjugated at the intended sites on the antibody without damaging the antibody structure or functionality is a significant challenge. Side reactions can lead to misfolded proteins or aggregation.
  • Purification Post-Conjugation: Separating the desired ADC from unconjugated antibody, free payload, and reaction byproducts is complex. Techniques like chromatography are essential but can be yield-limiting and costly.
• Analytical Characterization:
  • Comprehensive Testing: ADCs require extensive analytical testing to characterize their quality attributes, including antibody integrity, payload conjugation efficiency (DAR), free payload levels, aggregation, and purity. This involves a suite of advanced analytical techniques.
  • Reference Standards: Establishing and maintaining robust reference standards for complex ADC molecules is challenging.
• Scale-Up:
  • Process Reproducibility: Scaling up complex bioprocesses and chemical syntheses from laboratory to commercial scale while maintaining consistent quality and yield is a major hurdle. Each step must be validated and optimized for large-scale production.
  • Capacity: The specialized nature of ADC manufacturing means that dedicated capacity is often limited, requiring significant lead times for securing manufacturing slots.
• Regulatory Compliance:
  • Good Manufacturing Practices (GMP): Adherence to strict GMP regulations is paramount for all manufacturing steps. This includes rigorous documentation, validation of processes, and quality control.
  • CMC (Chemistry, Manufacturing, and Controls): Comprehensive CMC data packages are required for regulatory submissions, demonstrating control over the manufacturing process and product quality.

The successful manufacture of AVGEMSI relies on specialized CDMOs with proven expertise in all these areas, robust quality management systems, and a deep understanding of ADC technology.

What is the Regulatory Status and Market Access for AVGEMSI?

AVGEMSI, marketed as Elahere by ImmunoGen (now an AbbVie company), is approved for specific indications in ovarian cancer. Its regulatory status and market access are tied to these approvals and ongoing pharmacovigilance and potential label expansions.

Regulatory Approvals:

• United States:
  • Initial Approval (Accelerated): The U.S. Food and Drug Administration (FDA) granted accelerated approval to Elahere in November 2022 for the treatment of adult patients with folate receptor-alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. This approval was based on objective response rate (ORR) and duration of response (DoR) data from the SORAYA trial [1].
  • Conversion to Full Approval: ImmunoGen submitted data from the MIRASOL Phase 3 trial to the FDA in April 2023, aiming to convert the accelerated approval to full approval [2]. The MIRASOL trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy in the target patient population [3]. The FDA has since approved Elahere for full approval.
• European Union: ImmunoGen submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in September 2023 [4]. Regulatory review is ongoing.
• Other Jurisdictions: Submissions and reviews are likely underway or planned in other key pharmaceutical markets.

Market Access and Reimbursement:

• Pricing: As a novel oncology therapy with a specialized mechanism of action and targeting a specific patient population, Elahere is positioned as a premium-priced product. The exact pricing strategy and list price are subject to market dynamics and payer negotiations.
• Payer Negotiations: Obtaining favorable reimbursement from private and public payers is critical for market access. This typically involves demonstrating the drug's value proposition, including its clinical efficacy, safety profile, and potential impact on patient outcomes and healthcare resource utilization.
• Value-Based Agreements: In some markets, particularly in Europe, value-based agreements may be explored to align reimbursement with real-world outcomes.
• Patient Assistance Programs: ImmunoGen, and now AbbVie, will likely offer patient assistance programs to help eligible patients access Elahere, mitigating out-of-pocket costs.
• Market Competition: Elahere competes with other treatments for platinum-resistant ovarian cancer, including chemotherapy agents and other targeted therapies. Its FRα-targeting mechanism offers a differentiated approach.

The full approval by the FDA is a significant step, solidifying its long-term market presence in the United States. Successful market access in other major territories will depend on regulatory approvals and effective engagement with healthcare systems and payers.

What is the Intellectual Property Landscape for AVGEMSI?

The intellectual property (IP) landscape for AVGEMSI is crucial for its commercial exclusivity and provides a framework for market protection. This includes patents covering the drug substance, its manufacturing processes, formulations, and methods of use.

Key Patents and Exclusivity:

• Composition of Matter Patents: These are the most foundational patents, covering the novel chemical entity of mirvetuximab soravtansine itself. These patents typically have the longest patent terms. ImmunoGen would have secured such patents during the drug's development.
• Process Patents: Patents covering specific methods of manufacturing mirvetuximab soravtansine, including the synthesis of the antibody, the payload, the linker, and the conjugation process. These can provide protection even after composition of matter patents expire.
• Formulation Patents: Patents related to the specific pharmaceutical formulations of AVGEMSI that enhance stability, delivery, or patient compliance.
• Method of Use Patents: Patents covering the specific medical uses of AVGEMSI, such as its treatment of FRα-positive, platinum-resistant ovarian cancer.
• Data Exclusivity: Regulatory agencies grant periods of market exclusivity independent of patent protection upon drug approval. For example, in the U.S., new molecular entities (NMEs) generally receive five years of data exclusivity.
• Orphan Drug Exclusivity: If AVGEMSI is designated as an orphan drug for a specific indication, it may receive an additional period of exclusivity (seven years in the U.S.).

Patent Expiry and Generic Competition:

• Patent Term Extension: In many jurisdictions, patent terms can be extended to compensate for delays in obtaining regulatory approval. The actual expiry dates will depend on these extensions.
• Generic Entry: Once all relevant patents expire and data exclusivity periods have elapsed, generic manufacturers can seek approval to market biosimilar or generic versions of AVGEMSI. However, the complexity of ADC manufacturing makes direct bio-similar competition challenging and costly for generic companies, potentially extending the effective market exclusivity beyond patent expiry.
• Evergreening Strategies: Pharmaceutical companies often employ strategies to extend IP protection, such as developing new formulations, delivery methods, or expanding indications, which can lead to new patents and further exclusivity.

AbbVie's Role:

Since AbbVie's acquisition of ImmunoGen, they have inherited the entire IP portfolio for AVGEMSI. AbbVie is responsible for managing and defending these patents, as well as strategizing for future IP protection and lifecycle management.

Specific Patent Information:

Detailed patent information, including specific patent numbers, filing dates, and expiry dates, is publicly available through patent databases such as the USPTO (United States Patent and Trademark Office), EPO (European Patent Office), and WIPO (World Intellectual Property Organization). A comprehensive analysis would involve searching these databases for patents assigned to ImmunoGen and now AbbVie related to "mirvetuximab soravtansine" and its related compounds.

Key Takeaways

• AVGEMSI's supply chain relies on specialized CDMOs for its complex antibody, payload synthesis, and conjugation. Specific supplier names are proprietary.
• Manufacturing challenges include multi-step synthesis, potent payload handling, precise conjugation, and rigorous analytical characterization.
• AVGEMSI (Elahere) has received accelerated FDA approval for specific ovarian cancer indications and is pursuing full approval. EU review is ongoing.
• Market access depends on regulatory approvals, payer negotiations, and demonstrating therapeutic value against competing treatments.
• The IP landscape for AVGEMSI includes composition of matter, process, and method of use patents, providing commercial exclusivity managed by AbbVie.

Frequently Asked Questions

1. Are there any biosimilar or generic versions of AVGEMSI currently available? No, as of the latest available information, there are no biosimilar or generic versions of AVGEMSI (Elahere) approved or commercially available. The complexity of ADC manufacturing presents significant barriers to generic entry.
2. What is the projected market size for AVGEMSI? Market size projections for AVGEMSI vary based on factors such as market penetration, indication expansion, and competitive landscape. Industry analysts have forecasted significant revenue potential, particularly in the ovarian cancer market.
3. What is the primary target of AVGEMSI? AVGEMSI targets the folate receptor-alpha (FRα), which is overexpressed on the surface of certain cancer cells, including epithelial ovarian cancer.
4. What are the main safety concerns associated with AVGEMSI? Common side effects include ocular toxicities (e.g., blurred vision, dry eye), gastrointestinal issues (e.g., nausea, diarrhea), and neutropenia. Patients require careful monitoring for these adverse events.
5. What is the impact of AbbVie's acquisition of ImmunoGen on the AVGEMSI supply chain and strategy? AbbVie's acquisition is expected to leverage its established infrastructure, global reach, and resources to optimize AVGEMSI's manufacturing, expand its clinical development into new indications, and enhance its commercialization efforts. This may lead to increased investment in supply chain security and manufacturing capacity.

Citations

[1] U.S. Food & Drug Administration. (2022, November 14). FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. [Press release]. Retrieved from [FDA website] [2] ImmunoGen, Inc. (2023, April 24). ImmunoGen submits Biologics License Application to U.S. Food and Drug Administration for elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer. [Press release]. Retrieved from [ImmunoGen investor relations website] [3] ImmunoGen, Inc. (2023, January 8). MIRASOL Phase 3 trial of elahere (mirvetuximab soravtansine) met primary endpoint, demonstrating statistically significant improvement in progression-free survival in patients with platinum-resistant ovarian cancer. [Press release]. Retrieved from [ImmunoGen investor relations website] [4] ImmunoGen, Inc. (2023, September 7). ImmunoGen submits Marketing Authorisation Application to European Medicines Agency for elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer. [Press release]. Retrieved from [ImmunoGen investor relations website]